Cardiol Therapeutics Inc
- Country
- 🇨🇦Canada
- Ownership
- -
- Employees
- 22
- Market Cap
- -
- Introduction
Cardiol Therapeutics, Inc. is a clinical-stage life sciences company focused on the research and clinical of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. Its lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. The firm is conducting clinical studies to evaluate the efficacy and safety of CardiolRx in diseases affecting the heart: a Phase II multi-national, randomized, double-blind, placebo-controlled trial (the \"ARCHER\" trial) in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis. It is also involved in developing a novel subcutaneously administered drug formulation of cannabidiol intended for use in heart failure. The company was founded by David Elsley, Eldon Smith, and Anthony Bolton on January 19, 2017 and is headquartered in Oakville, Canada.
Clinical Trials
8
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials
CardiolRx in Recurrent Pericarditis Following IL-1 Blocker Cessation
- First Posted Date
- 2024-11-27
- Last Posted Date
- 2025-08-28
- Lead Sponsor
- Cardiol Therapeutics Inc.
- Target Recruit Count
- 110
- Registration Number
- NCT06708299
- Locations
- 🇺🇸
UCI Health, Irvine, California, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
Impact of CardiolRxTM on Recurrent Pericarditis (MAvERIC-Pilot)
- First Posted Date
- 2022-08-10
- Last Posted Date
- 2025-07-04
- Lead Sponsor
- Cardiol Therapeutics Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT05494788
- Locations
- 🇺🇸
Pima Heart and Vascular Clinical Research, Tucson, Arizona, United States
🇺🇸MedStar Health Research Institute, Washington, District of Columbia, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Impact of CardiolRx on Myocardial Recovery in Patients With Acute Myocarditis
- First Posted Date
- 2022-01-06
- Last Posted Date
- 2025-03-12
- Lead Sponsor
- Cardiol Therapeutics Inc.
- Target Recruit Count
- 109
- Registration Number
- NCT05180240
- Locations
- 🇺🇸
MedStar Heart and Vascular Institute, Washington, District of Columbia, United States
🇺🇸Massachusetts General Hospital site, Boston, Massachusetts, United States
🇺🇸Minneapolis Heart Institute Foundation, Minneapolis, Minnesota, United States
Cannabidiol in Patients With COVID-19 and Cardiovascular Disease or Risk Factors
- Conditions
- Cardiovascular DiseasesCardiovascular Risk FactorCOVID-19
- Interventions
- Drug: PlaceboDrug: Cannabidiol, pharmaceutically produced with < 5 ppm THC
- First Posted Date
- 2020-11-04
- Last Posted Date
- 2025-07-25
- Lead Sponsor
- Cardiol Therapeutics Inc.
- Target Recruit Count
- 90
- Registration Number
- NCT04615949
- Locations
- 🇺🇸
Valleywise Health Medical Center, Phoenix, Arizona, United States
🇺🇸JY Research Institute, Cutler Bay, Florida, United States
🇺🇸Westchester General Hospital, Miami, Florida, United States
News
Cardiol Therapeutics Stock Plunges 20% as CBD-Based CardiolRx Misses Primary Endpoints in Myocarditis Trial
Cardiol Therapeutics' cannabidiol-based therapy CardiolRx failed to meet co-primary endpoints in the Phase II ARCHER trial for myocarditis, with extracellular volume reduction missing statistical significance (p=0.0538).
Cardiol's CRD-38 Shows Promise in Heart Failure Treatment with Novel Cannabidiol Approach
New data published in JACC demonstrates CRD-38's ability to improve cardiac function and reduce inflammation through its unique cannabidiol-based mechanism of action.
Cardiol Therapeutics Leadership Invests Following Positive Phase II Pericarditis Trial Data
Cardiol Therapeutics executives and board members increased their holdings after promising Phase II trial results for CardiolRx™ in recurrent pericarditis.
Penny Stocks to Watch: GeoVax, Cardiol Therapeutics, and Vuzix Show Promise
GeoVax Labs' COVID-19 vaccine candidate, GEO-CM04S1, demonstrates positive Phase 2 trial results in chronic lymphocytic leukemia (CLL).
Cardiol Therapeutics Advances CardiolRx™ for Recurrent Pericarditis to Phase 3 Trial
Cardiol Therapeutics is advancing its lead drug, CardiolRx™, to a Phase 3 clinical trial (MAVERIC) for patients with recurrent pericarditis at high risk of recurrence.
CardiolRx Shows Promise in Recurrent Pericarditis: Phase II MAvERIC-Pilot Study Results
Cardiol Therapeutics' CardiolRx demonstrated lasting improvements in pericarditis symptoms over a 26-week extension in the Phase II MAvERIC-Pilot study.
Cardiol Therapeutics' CardiolRx Shows Promise in Phase 2 Pericarditis Study
Cardiol Therapeutics' CardiolRx demonstrated significant improvements in pericarditis pain and inflammation over 26 weeks in a Phase 2 trial.
Cardiol Therapeutics Advances CardiolRx into Phase III Trial for Recurrent Pericarditis Following Positive Phase II Results
Cardiol Therapeutics is advancing its drug, CardiolRx, into a Phase III clinical trial (MAVERIC-3) for recurrent pericarditis after promising Phase II results.
Cardiol Therapeutics' CardiolRx Shows Sustained Efficacy in Recurrent Pericarditis, Poised for Phase III Trials
Cardiol Therapeutics' CardiolRx demonstrated sustained pain relief in recurrent pericarditis patients over six months, with average pain scores decreasing from 5.8 to 1.5.
Cardiol Therapeutics' CardiolRx Shows Promise in Phase II Trial for Recurrent Pericarditis
Cardiol Therapeutics' CardiolRx demonstrated significant improvements in pain and inflammation in patients with recurrent pericarditis during a Phase II open-label study.